RxDoctor Payments Data

Juan Pineda Lopez, MD

General Practice · Orlando, FLNPI 1104292846

Payments from drug & device makers

$447in general payments, 2019–2025

Across 26 payments — averaging $17.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Esperion Therapeutics, Inc.$105
  • Novo Nordisk$94
  • AbbVie$37
  • Sanofi-aventis U.S. LLC$36
  • Johnson & Johnson$32
  • Kowa Pharmaceuticals America, Inc.$31
  • plus $113 from 6 others

What the payments were for

  • Food & beverage$447100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$447 in reported general payments places this provider in the 60th percentile of 6,901 general practice providers in Florida.

See all general practice providers in Florida

Medicare billing

Part B allowed, 2024
$9,657
Medicare patients
36
Services billed
101

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide71$105,470
EliquisApixaban76$105,413
JardianceEmpagliflozin59$77,151
TrulicityDulaglutide45$45,814
EntrestoSacubitril/Valsartan27$38,432
XareltoRivaroxaban23$35,178
JanuviaSitagliptin Phosphate21$32,915
FarxigaDapagliflozin Propanediol15$24,956
Tresiba Flextouch U-200Insulin Degludec28$21,608
Trelegy ElliptaFluticasone/Umeclidin/Vilanter24$16,431
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog12$13,325
Lantus SolostarInsulin Glargine,hum.Rec.Anlog95$12,997
BrilintaTicagrelor15$12,806
Atorvastatin Calcium1,004$8,110
Albuterol Sulfate HfaAlbuterol Sulfate241$6,466

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$94$105,47071 claims
AstraZenecaFarxiga, Brilinta, Symbicort$16$40,59642 claims
NovartisEntresto$21$38,43227 claims
Johnson & JohnsonXarelto$32$35,17823 claims
AbbVieLumigan, Synthroid$37$6,75735 claims
Sanofi-aventis U.S. LLCLantus$36$4,28830 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 6,901 general practice providers in Florida.

Other general practice in Orlando

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →